Home > Signaling Pathways>New Products>New2>ACT-660602
ACT-660602

This product is for research use only, not for human use. We do not sell to patients.

ACT-660602
For small sizes, please check our retail website as below: www.invivochem.com
Size Price
250mgGet quote
500mgGet quote
1gGet quote
email: [email protected]        [email protected]

Cat #: V42012 CAS #: 1646267-59-5 Purity ≥ 99%

Description: ACT-660602 (ACT660602) is a novel antagonist of chemokine receptor (CXCR3) with the potential for autoimmune diseases. It inhibits CXCR3 with an IC50 value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. It reduced recruitment of the CXCR3+ CD8+ T cell in the bronchoalveolar lavage compartment when administered orally at a dose of 30 mg/kg.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular FormulaC20H20F6N8OS
CAS No.1646267-59-5
ProtocolIn VitroACT-660602 (ACT660602 shows selectivity to CXCR3 over hERG, with IC50s of 18 μM (hERG)[1]. ACT-660602 (112 nM; 6 h) inhibits cell migration and improves the metabolic stability[1]. ACT-660602 (5, 20, 100 or 500 nM) displays an non-competitive binding mode to CXCL10 and CXCL11 in different concentration, with more stable IC50s[1]. Cell Migration Assay [1] Cell Line: CD3/CD28-activated primary human T cells Concentration: 112 nM Incubation Time: 45 min Result: Inhibited cell migration.
In VivoACT-660602 (ACT660602 (1 μM; 6 h) intrinsic metabolic clearance (CLint) in human, rat, mouse liver microsomes (HLM, RLM, MLM)[1]. ACT-660602 (30 mg/kg; p.o.; once daily) displays anti-inflammatory activity and exerts efficacy in the mouse model of acute lung ingury[1]. Range for Pharmacokinetics of ACT-660602[1] Animal Route Dose (range) (mg/kg) Cmax (range) (ng/mL) Tmax (range) (h) AUC (range) (ng•h/mL) F (%) CL (range) (mL/min/kg) Vss (range) (L/kg) T1/2 (range) (h) Dog p.o. 2 1380 1 20000 8 1.3 1.7 14.5 i.v. 0.5 1300-1450 0.5-2.0 10400-32000 / 0.6-3.0 1.6-1.7 6.3- Rat p.o. 2 1520 0.5 14000 80 1.9 1.1 7.1 i.v. 0.5 1250-1860 0.5-1.0 11600-15641 / 1.9-1.9 0.9-1.3 5.7-8.8 Animal Model: LPS-induced lung inflammation model (72 h post LPS challenge)[1] Dosage: 30 mg/kg Administration: Oral gavage; once daily Result: Significantly reduced recruitment of the CXCR3+ CD8+ T cell in the bronchoalveolar lavage compartment.
These protocols are for reference only. InvivoChem does not independently validate these methods.
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.